Scarica l'app Stockscreener
3.00
2.04%
0.06
Dopo l'orario di chiusura:
3.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:2.940|Chg%:+0.060 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution? - kalkinemedia.com
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT - MarketBeat
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Yahoo Finance Australia
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Altimmune Reports Q2 2026 Financial Results and SEC Filing Highlighting Increased Assets and Equity Raise - kalkinemedia.com
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary - TradingView
Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial - Stock Titan
Altimmune (ALT) Advances Clinical Trials Amidst High Price-to-Sa - GuruFocus
Altimmune Releases Q2 2026 Financial Results - AlphaStreet
William Blair Maintains Altimmune(ALT.US) With Hold Rating - Moomoo
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Altimmune Q2 EPS $(0.12) beats $(0.15) estimate - scanx.trade
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise - Investing.com Australia
Altimmune Q2 Earnings Call Highlights - MarketBeat
Altimmune (ALT) Q2 Earnings Beat Expectations but Remain Unprofi - GuruFocus
Q2 2026 Altimmune Inc Earnings Call Transcript - GuruFocus
Form 8K Altimmune Inc For: 12 August By Investing.com - Investing.com South Africa
Altimmune posts smaller-than-expected Q2 net loss per share - TradingView
Altimmune posts $22.8M Q2 net loss, $519M cash; advances pemvidutide Phase 3 and Phase 2 programs - TradingView
Altimmune Announces Second Quarter 2026 Financial Results and Business Update - The Manila Times
Altimmune Reports $22.8 Million Q2 Loss and Advances Pemvidutide Trials - Quiver Quantitative
Altimmune (NASDAQ:ALT): What Could Today’s clinical evidence and program focus Update Reveal? - Kalkine Media
Altimmune Inc (ALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Altimmune (ALT) Q2 Earnings Preview: Unpacking Valuation and Guru Ownership Signals - GuruFocus
Altimmune (ALT) Earnings Date and Reports 2026 $ALT - MarketBeat
Altimmune Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Weekly Recap: Altimmune (ALT) PERFORMA Phase 3 launch and Aug 12 results - TradingView
Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Altimmune, Inc. (ALT) options chain – Yahoo Finance - sg.finance.yahoo.com
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Altimmune to discuss its liver-treatment candidate Aug. 12 - Stock Titan
ALT Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
Altimmune (ALT) Projected to Release Quarterly Earnings on Tuesday - marketbeat.com
Altimmune (ALT) CSO acquires 875 ESPP shares at $2.414 - Stock Titan
Altimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan - Stock Titan
Altimmune (ALT) Begins Enrollment in Phase 3 Trial Amid High Pri - GuruFocus
Altimmune begins phase 3 trial of pemvidutide for MASH - Investing.com
Altimmune begins phase 3 trial of pemvidutide for MASH By Investing.com - Investing.com Nigeria
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - The Manila Times
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):